Compare · NAVB vs ORKA
NAVB vs ORKA
Side-by-side comparison of Navidea Biopharmaceuticals Inc. (NAVB) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAVB and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.47B, about 215.2x NAVB ($30.1M).
- ORKA has hit the wire 14 times in the past 4 weeks while NAVB has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NAVB).
- Company
- Navidea Biopharmaceuticals Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $30.1M
- $6.47B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 0
- 14
- Recent ratings
- 0
- 11
Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Latest NAVB
- Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
- Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
- Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
- Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
- Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
- SEC Form SC 13D/A filed by Navidea Biopharmaceuticals Inc. (Amendment)
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Sandler Laura Lee sold $86,713 worth of shares (906 units at $95.71), decreasing direct ownership by 0.38% to 235,478 units (SEC Form 4) (withholding tax)
- Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.